Latest From Jessica Merrill
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
As Medicare drug price negotiations creep closer to reality, industry leaders are turning attention to the challenges of implementation and commercial concerns.
The company presented its pipeline to investors during an R&D day, outlining expansion plans for Voxzogo and Roctavian as well as several early pipeline drugs.
Competing in the obesity market will require significant investment, which Amgen is preparing for, CEO Robert Bradway told investors during the Morgan Stanley Healthcare conference.
The two drug developers announced a collaboration to develop and commercialize multiple cancer programs. Nurix will receive $60m up front.
President of Innovative Medicines International and chief commercial officer Marie-France Tschudin will leave Novartis after nearly seven years.